Aortic Valve Stenosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Aortic Valve Stenosis. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Aortic Valve Stenosis receives a directional strategic score of 60/100, combining unmet need (70/100), competitive intensity (96/100, where higher means more competition) and market attractiveness (89/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA.

The reproducible entity is Patsnap disease ID 61df94b9509144f985b94ebbb0669214 with MeSH identifier D001024. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Heart Disease and Stroke Statistics—2022 Update Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

Aortic Valve Disorders ICD-9 424.1; ICD-10 I35. 2019: Mortality—16 119. Any-mention mortality—35 766. 2018: Hospital discharges—101 000. Prevalence • Prevalence of aortic stenosis by echocardiography was 4.3% among individuals ≥70 years of age in the Icelandic AGES-Reykjavik cohort.7 • In younger age groups, the most prevalent cause of aortic stenosis is bicuspid aortic valve, the most common form of congenital HD. In an Italian study of 817 primary school students, the preva­ lence of bicuspid aortic valve was 0.5% (95% CI, 0.13%–1.2%).8 Incidence • Nationally representative data from Sweden dem­ onstrate an age-adjusted incidence of aortic steno­ sis from 15.0 to 11.4 per 100 000 males and from 9.8 to 7.1 per 100 000 females between the years 1989 to 1991 and 2007 to 2009.9 • In the Norwegian Tromsø study, the incidence of new aortic stenosis was 4.9 per 1000 per year, with the initial mean age of participants being 60 years.10 • In the Canadian CANHEART aortic stenosis study, absolute incidence of severe aortic stenosis among individuals >65 years of age was 144 per 100 000 person-years (169 and 127 per 100 000 person- years in males and females, respectively).11 Lifetime Risk and Cumulative Incidence • The number of elderly patients with calcific aortic stenosis is projected to more than double by 2050 in both the United States and Europe according to a simulation model in 7 decision analysis studies.12 • The pooled prevalence of all AS in the elderly was 12.4% (95% CI, 6.6%–18.2%), and the prevalence of severe AS was 3.4% (95% CI, 1.1%–5.7%).12

Review the epidemiology source

Epidemiology evidence 2: Heart Disease and Stroke Statistics—2020 Update Heart Disease and Stroke Statistics— 2020 Update

Aortic Valve Disorders (See Chart 21-1) ICD-9 424.1; ICD-10 I35. 2017: Mortality—16 827. Any-mention mortality 35 434. 2016: Hospital discharges—91 000. Prevalence • Prevalence of aortic stenosis by echocardiography was 4.3% among individuals ≥70 years of age in the Icelandic AGES-Reykjavik cohort.6 • In younger age groups, the most prevalent cause of aortic stenosis is bicuspid aortic valve, the most common form of congenital HD. In an Italian study of 817 primary school students, the preva- lence of bicuspid aortic valve was 0.5% (95% CI, 0.13%–1.2%).7 Incidence • Nationally representative data from Sweden dem- onstrate an age-adjusted incidence of aortic steno- sis from 15.0 to 11.4 per 100 000 males and from 9.8 to 7.1 per 100 000 females, between the years 1989 to 1991 and 2007 to 2009.8 • In the Norwegian Tromsø study, the incidence of new aortic stenosis was 5 per 1000 per year, with the initial mean age of participants being 60 years.9 • In the Canadian CANHEART aortic stenosis study, absolute incidence of severe aortic stenosis among individuals >65 years of age was 144 per 100 000 person-years (169 and 127 per 100 000 person- years in males and females, respectively).10 Lifetime Risk and Cumulative Incidence • The number of elderly patients with calcific aortic stenosis is projected to more than double by 2050 in both the United States and Europe based on a simulation model in 7 decision analysis studies. In the Icelandic AGES-Reykjavik study alone, pro- jections suggest a doubling in prevalence among those with severe aortic stenosis who are ≥70 years of age by 2

Review the epidemiology source

Epidemiology evidence 3: Heart Disease and Stroke Statistics—2021 Update

• Previously undiagnosed, predominantly mild val- vular HD was found in 51% of 2500 individuals ≥65 years of age from a primary care population screened with transthoracic echocardiography. The prevalence of undiagnosed moderate or severe val- vular HD was 6.4%.4 In a population-based study of 1818 Hispanic/Latino people (mean age, 55 years; 57% female), the prevalence of any valvular HD was 3.1%. The prevalence of regurgitant or stenotic val- vular HD of moderate or greater severity was 2.6%.5 Incidence • In a report using a Swedish nationwide register to identify all patients with a first diagnosis of valvular HD at Swedish hospitals between 2003 and 2010 (N=10 164 211), the incidence of valvular HD was 63.9 per 100 000 person-years, with aortic steno- sis (47.2%), MR (24.2%), and aortic regurgitation (18.0%) contributing most of the valvular diagno- ses. The majority of valvulopathies were diagnosed in the elderly (68.9% in subjects ≥65 years of age). Incidences of aortic regurgitation, aortic stenosis, and MR were higher in males, who were also more frequently diagnosed at an earlier age. Mitral ste- nosis incidence was higher in females.6 Aortic Valve Disorders ICD-9 424.1; ICD-10 I35. 2018: Mortality—16 322. Any-mention mortality 35 105. 2016: Hospital discharges—91 000. Prevalence • Prevalence of aortic stenosis by echocardiography was 4.3% among individuals ≥70 years of age in the Icelandic AGES-Reykjavik cohort.7 • In younger age groups, the most prevalent cause of aortic stenosis is bicuspid aortic valve, the most com- mon form of congenital HD. In an Italian stud

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Aortic Valve Stenosis, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Aortic Valve Stenosis thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: MYH7

Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle.

The mechanism anchor is MYH7. It is a pathway hypothesis, not a claim that every Aortic Valve Stenosis patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 2122 registered studies. Recent sampled records include:

• NCT07755904 — BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy (LIONHEART-HCM); Not yet recruiting; Phase 3; sponsor Braveheart Bio, Inc.; enrollment 210.
• NCT07756398 — Importance of Point-of-Care Ultrasound for Early Detection of Valvular and Cardiac Diseases (IMPROVE) (IMPROVE); Not yet recruiting; Not Applicable; sponsor The University of Texas Southwestern Medical Center; enrollment 1088.
• NCT07751965 — Prospective Multicenter Study Evaluating Myval TAVR Safety and Effectiveness in High-risk Severe AR (MARVELTAVI); Not yet recruiting; Not Applicable; sponsor Ceric Sàrl; enrollment 164.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

The search returned 3 recent directly matched transaction records:

• CORXEL and Sanofi Announce an Agreement for Aficamten in Greater China Markets (2024-12-20). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.
• Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan (2024-11-19). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.
• Novo Nordisk complete acquisition of Cardior Pharmaceuticals GmbH (2024-03-25). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate MYH7 relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Aortic Valve Stenosis merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if MYH7 modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Aortic Valve Stenosis is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.